Royal Bank of Canada Stock
€161.98
Your prediction
Royal Bank of Canada Stock
Pros and Cons of Royal Bank of Canada in the next few years
Pros
Cons
Performance of Royal Bank of Canada vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Royal Bank of Canada | -0.420% | 1.031% | 7.951% | 43.187% | 11.213% | 93.022% | 89.846% |
| Canadian Imperial Bank of Commerce | -4.960% | 0.925% | 5.372% | 64.403% | 27.195% | 151.904% | 106.405% |
| Bank of Montreal | -1.300% | 3.375% | 7.923% | 51.708% | 25.773% | 81.383% | 64.074% |
| Carver Bancorp Inc | 0.000% | -5.926% | -13.605% | -0.781% | 8.547% | - | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When first glancing at the financials of the company RBC, known under the US symbol RY from the banking services industry, it's noticeable that the company holds a substantial market capitalization, which as of the latest data stands at approximately 174.77 billion USD. This indicates a strong market presence. The Price to Earnings (P/E) ratio is moderate at 11.83, suggesting the market prices its earnings reasonably in comparison to some peers.
Now, diving into a more detailed analysis, there are several pros and cons to consider:
Looking at valuations, RBC has a forward P/E of 10.75, which is lower than its trailing P/E, hinting that the earnings are expected to grow. The Price to Sales (P/S) ratio of 3.257 is relatively high for the banking sector, suggesting that RBC’s stock might be trading at a premium based on its sales. The Price to Book (P/B) ratio at 1.584, which is reasonable for the industry, provides investors a sense of how much they’re paying for the net assets of the company.
Comments
News
Royal Bank Of Canada Q2 Earnings Call Highlights
Key Points
- Interested in Royal Bank Of Canada? Here are five stocks we like better.
- Royal Bank of Canada delivered a strong second quarter with CAD 5.5 billion in earnings and CAD 5.6 billion
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance
Key Points
- Interested in Mirum Pharmaceuticals, Inc.? Here are five stocks we like better.
- LIVMARLI continues to drive Mirum’s commercial momentum, with first-quarter 2026 net sales of $114
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout
Key Points
- Interested in Corbus Pharmaceuticals Holdings, Inc.? Here are five stocks we like better.
- CRB-701 will get more mature cancer data at ASCO, including the first reported duration of